Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Benefits of Peanut Desensitization May Not Last

Publish date:: September 23, 2019

Key clinical point: Discontinuing or reducing peanut OIT to 300 mg daily increased the potential of regaining an allergic reaction.

Major finding: At week 156, after a year of avoiding peanut, 37% of patients reduced to 300 mg of peanut OIT passed an allergy challenge, compared with 13% of those who totally discontinued OIT and 4% of a placebo group.

Study details: The data come from a randomized, phase 2 study of 120 individuals aged 7-55 years with peanut allergies.

Disclosures: The National Institutes of Health supported the study. The researchers had no financial conflicts to disclose.

Citation:

Chinthrajah RS et al. Lancet. 2019 Sep 12. doi: 10.1016/S0140-6736(19)31793-3.

This Week's Must Reads

Frequent soaks ease pediatric atopic dermatitis,

SZC passes extension test for hyperkalemia,

BCL11A-directed gene therapy advances in sickle cell disease,

Pimavanserin reduced dementia-related psychotic symptoms without affecting cognition,

Asthma exacerbation in pregnancy impacts moms, babies,

Must Reads in Dermatology

Frequent soaks ease pediatric atopic dermatitis,

Naturopaths Emphasize Role of Diet in Atopic Dermatitis,

Early Onset of Atopic Dermatitis Linked to Poorer Control,

Skin Barrier Dysfunction Mutations Vary by Race, Disease Persistence in Children With AD,

Melanoma Incidence Drops in Younger Age Groups,